Neuroprotective effect of protein kinase Cδ inhibitor rottlerin in cell culture and animal models of Parkinson's disease

Journal of Pharmacology and Experimental Therapeutics

Volumn 322, Issue 3, 2007, Pages 913-922

  Zhang, Danhui ^a   Anantharam, Vellareddy ^a   Kanthasamy, Arthi ^a   Kanthasamy, Anumantha G ^a  

^a IOWA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3,4 DIHYDROXYPHENYLACETIC ACID; CASPASE 3; DOPAMINE; PROTEIN KINASE C DELTA; ROTTLERIN; SMALL INTERFERING RNA; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DEATH; CELL LOSS; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; EMBRYO; ENZYME ACTIVATION; ENZYME ACTIVITY; EXPERIMENTAL MODEL; LOCOMOTION; MESENCEPHALON; MOTOR DYSFUNCTION; MOUSE; NERVE CELL CULTURE; NEURITE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; STEREOMETRY; STRIATE CORTEX; SUBSTANTIA NIGRA; TREATMENT DURATION;

ACETOPHENONES; ANIMALS; BENZOPYRANS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; MESENCEPHALON; MICE; NEURONS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; PROTEIN KINASE C-DELTA; SUBSTANTIA NIGRA;

EID: 34548101125     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.124669     Document Type: Article

References (42)

1. Akita Y (2002) Protein kinase C-epsilon (PKC-epsilon): its unique structure and function. J Biochem 132:847-852.
2. Anantharam V, Kitazawa M, Wagner J, Kaul S, and Kanthasamy AG (2002) Caspase-3-dependent proteolytic cleavage of protein kinase Cdelta is essential for oxidative stress-mediated dopaminergic cell death after exposure to methylcyclopentadienyl manganese tricarbonyl. J Neurosci 22:1738-1751.
3. Aronowski J and Labiche LA (2003) Perspectives on reperfusion-induced damage in rodent models of experimental focal ischemia and role of gamma-protein kinase C. ILAR J 44:105-109.
4. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
5. Burke RE (2007) Kinase signaling pathways: potential therapeutic targets in Parkinson's disease. Future Neurol 2:39-49.
6. Choi BH, Hur EM, Lee JH, Jun DJ, and Kim KT (2006) Protein kinase Cdelta-mediated proteasomal degradation of MAP kinase phosphatase-1 contributes to glutamate-induced neuronal cell death. J Cell Sci 119:1329- 1340.
7. Couzin J (2007) Clinical research. Testing a novel strategy against Parkinson's disease. Science 315:1778.
8. Davies SP, Reddy H, Caivano M, and Cohen P (2000) Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351:95-105.
9. Du Y, Ma Z, Lin S, Dodel RC, Gao F, Bales KR, Triarhou LC, Chernet E, Perry KW, Nelson DL, et al. (2001) Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci U S A 98:14669-14674.
10. Duan W, Zhu X, Ladenheim B, Yu QS, Guo Z, Oyler J, Cutler RG, Cadet JL, Greig NH, and Mattson MP (2002) p53 inhibitors preserve dopamine neurons and motor function in experimental parkinsonism. Ann Neurol 52:597-606.
11. Fiszman ML, Zuddas A, Masana MI, Barker JL, and di Porzio U (1991) Dopamine synthesis precedes dopamine uptake in embryonic rat mesencephalic neurons. J Neurochem 56:392-399.
12. Greenamyre JT and Hastings TG (2004) Biomedicine. Parkinson's-divergent causes, convergent mechanisms. Science 304:1120-1122.
13. Gschwendt M, Muller HJ, Kielbassa K, Zang R, Kittstein W, Rincke G, and Marks F (1994) Rottlerin, a novel protein kinase inhibitor. Biochem Biophys Res Commun 199:93-98.
14. Iwashita A, Yamazaki S, Mihara K, Hattori K, Yamamoto H, Ishida J, Matsuoka N, and Mutoh S (2004) Neuroprotective effects of a novel poly(ADP-ribose) polymerase-1 inhibitor, 2-[3-[4-(4-chlorophenyl)-1-piperazinyl] propyl]-4(3H)-quinazolinone (FR255595), in an in vitro model of cell death and in mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J Pharmacol Exp Ther 309:1067-1078.
15. Kanthasamy AG, Kitazawa M, Kanthasamy A, and Anantharam V (2003) Role of proteolytic activation of protein kinase Cdelta in oxidative stress-induced apoptosis. Antioxid Redox Signal 5:609-620.
16. Kaul S, Anantharam V, Yang Y, Choi CJ, Kanthasamy A, and Kanthasamy AG (2005) Tyrosine phosphorylation regulates the proteolytic activation of protein kinase Cdelta in dopaminergic neuronal cells. J Biol Chem 280:28721-28730.
17. Kaul S, Kanthasamy A, Kitazawa M, Anantharam V, and Kanthasamy AG (2003) Caspase-3 dependent proteolytic activation of protein kinase C delta mediates and regulates 1-methyl-4-phenylpyridinium (MPP+)-induced apoptotic cell death in dopaminergic cells: relevance to oxidative stress in dopaminergic degeneration. Eur J Neurosci 18:1387-1401.
18. Kelly KJ, Sutton TA, Weathered N, Ray N, Caldwell EJ, Plotkin Z, and Dagher PC (2004) Minocycline inhibits apoptosis and inflammation in a rat model of ischemic renal injury. Am J Physiol 287:F760-F766.
19. Kitazawa M, Anantharam V, and Kanthasamy AG (2001) Dieldrin-induced oxidative stress and neurochemical changes contribute to apoptopic cell death in dopaminergic cells. Free Radic Biol Med 31:1473-1485.
20. Kitazawa M, Anantharam V, and Kanthasamy AG (2003) Dieldrin induces apoptosis by promoting caspase-3-dependent proteolytic cleavage of protein kinase Cdelta in dopaminergic cells: relevance to oxidative stress and dopaminergic degeneration. Neuroscience 119:945-964.
21. Kitazawa M, Anantharam V, Kanthasamy A, and Kanthasamy AG (2004) Dieldrin promotes proteolytic cleavage of poly(ADP-ribose) polymerase and apoptosis in dopaminergic cells: protective effect of mitochondrial anti-apoptotic protein Bcl-2. Neurotoxicology 25:589-598.
22. Latchoumycandane C, Anantharam V, Kitazawa M, Yang Y, Kanthasamy A, and Kanthasamy AG (2005) Protein kinase Cdelta is a key downstream mediator of manganese-induced apoptosis in dopaminergic neuronal cells. J Pharmacol Exp Ther 313:46-55.
23. Maguire-Zeiss KA, Short DW, and Federoff HJ (2005) Synuclein, dopamine and oxidative stress: co-conspirators in Parkinson's disease. Brain Res Mol Brain Res 134:18-23.
24. Maroney AC, Glicksman MA, Basma AN, Walton KM, Knight E, Murphy CA, Bartlett BA, Finn JP, Angeles T, Matsuda Y, et al. (1998) Motoneuron apoptosis is blocked by CEP-1347 (KT 7515), a novel inhibitor of the JNK signaling pathway. J Neurosci 18:104-111.
25. Maruyama W, Akao Y, Carrillo MC, Kitani K, Youdium MB, and Naoi M (2002) Neuroprotection by propargylamines in Parkinson's disease: suppression of apoptosis and induction of prosurvival genes. Neurotoxicol Teratol 24:675-682.
26. Matthews RT, Ferrante RJ, Klivenyi P, Yang L, Klein AM, Mueller G, Kaddurah-Daouk R, and Beal MF (1999) Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp Neurol 157:142-149.
27. National Institute of Neurological Disorders and Stroke (2006) A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 66:664-671.
28. Obata T (2006) Effect of desferrioxamine, a strong iron (III) chelator, on 1-methyl-4-phenylpyridinium ion (MPP+)-induced hydroxyl radical generation in the rat striatum. Eur J Pharmacol 539:34-38.
29. Parashar B, Latha Shankar S, O'Guin K, Butler J, Vikram B, and Shafit-Zagardo B (2005) Inhibition of human neuroblastoma cell growth by CAY10404, a highly selective Cox-2 inhibitor. J Neurooncol 71:141-148.
30. Ravina BM, Fagan SC, Hart RG, Hovinga CA, Murphy DD, Dawson TM, and Marler JR (2003) Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. Neurology 60:1234-1240.
31. Saito N and Shirai Y (2002) Protein kinase C gamma (PKC gamma): function of neuron specific isotype. J Biochem 132:683-687.
32. Samokhin GP, Jirousek MR, Ways DK, and Henriksen RA (1999) Effects of protein kinase C inhibitors on thromboxane production by thrombin-stimulated platelets. Eur J Pharmacol 386:297-303.
33. Saporito MS, Brown EM, Miller MS, and Carswell S (1999) CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons in vivo. J Pharmacol Exp Ther 288:421-427.
34. Shults CW and Haas R (2005) Clinical trials of coenzyme Q10 in neurological disorders. Biofactors 25:117-126.
35. Smith MA, Perry G, Zhu X, and Haoudi (2006) A Neurodegenerative diseases: mechanisms and therapies. J Biomed Biotechnol 2006:47539.
36. Soltoff SP (2001) Rottlerin is a mitochondrial uncoupler that decreases cellular ATP levels and indirectly blocks protein kinase Cδ tyrosine phosphorylation. J Biol Chem 276:37986-37992.
37. Tarnopolsky MA and Beal MF (2001) Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders. Ann Neurol 49:561-574.
38. Thiruchelvam MJ, Powers JM, Cory-Slechta DA, and Richfield EK (2004) Risk factors for dopaminergic neuron loss in human alpha-synuclein transgenic mice. Eur J Neurosci 19:845-854.
39. Varma DR, Sareen KN, Roy AK, and Gujral ML (1959) Oral contraptive-part III. Further observations on the antifertility effect of rottlerin. Indian J Physiol Pharmacol 3:168-172.
40. West AB, Moore DJ, Biskup S, Bugayenko A, Smith WW, Ross CA, Dawson VL, and Dawson TM (2005) Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A 102:16842-16847.
41. Yang Y, Kaul S, Zhang D, Anantharam V, and Kanthasamy AG (2004) Suppression of caspase-3-dependent proteolytic activation of protein kinase C delta by small interfering RNA prevents MPPδ-induced dopaminergic degeneration. Mol Cell Neurosci 25:406-421.
42. Yoshida K, Miki Y, and Kufe D (2002) Activation of SAPK/JNK signaling by protein kinase Cδ in response to DNA damage. J Biol Chem 277:48372-48378.